Access the full text.
Sign up today, get DeepDyve free for 14 days.
A. May, Thomas Wang (2008)
Biomarkers for cardiovascular disease: challenges and future directions.Trends in molecular medicine, 14 6
N. Seman, A. Witasp, Wan Mohamud, B. Anderstam, K. Brismar, P. Stenvinkel, H. Gu (2013)
Evaluation of the Association of Plasma Pentraxin 3 Levels with Type 2 Diabetes and Diabetic Nephropathy in a Malay PopulationJournal of Diabetes Research, 2013
A. Juutilainen, S. Lehto, T. Rönnemaa, K. Pyörälä, M. Laakso (2005)
Type 2 diabetes as a "coronary heart disease equivalent": an 18-year prospective population-based study in Finnish subjects.Diabetes care, 28 12
Rui Wang, Jietao Zhang, Wenchao Hu (2016)
Association of serum pentraxin 3 concentrations with diabetic nephropathyJournal of Investigative Medicine, 64
G. Vilahur, L. Badimón (2015)
Biological actions of pentraxins.Vascular pharmacology, 73
A. Baragetti, M. Knoflach, I. Cuccovillo, L. Grigore, M. Casula, K. Garlaschelli, A. Mantovani, G. Wick, S. Kiechl, J. Willeit, B. Bottazzi, A. Catapano, G. Norata (2014)
Pentraxin 3 (PTX3) plasma levels and carotid intima media thickness progression in the general population.Nutrition, metabolism, and cardiovascular diseases : NMCD, 24 5
M. Suliman, M. Yılmaz, J. Carrero, A. Qureshi, M. Sağlam, O. Ipçioğlu, M. Yenıcesu, Mengli Tong, O. Heimbürger, P. Bárány, A. Alvestrand, B. Lindholm, P. Stenvinkel (2008)
Novel links between the long pentraxin 3, endothelial dysfunction, and albuminuria in early and advanced chronic kidney disease.Clinical journal of the American Society of Nephrology : CJASN, 3 4
C. Stehouwer, Y. Smulders (2006)
Microalbuminuria and risk for cardiovascular disease: Analysis of potential mechanisms.Journal of the American Society of Nephrology : JASN, 17 8
R. Latini, A. Maggioni, G. Peri, L. Gonzini, D. Lucci, P. Mocarelli, L. Vago, F. Pasqualini, S. Signorini, D. Soldateschi, L. Tarli, C. Schweiger, C. Fresco, R. Cecere, G. Tognoni, A. Mantovani (2004)
Prognostic Significance of the Long Pentraxin PTX3 in Acute Myocardial InfarctionCirculation, 110
M. Drakopoulou, K. Toutouzas, A. Michelongona, D. Tousoulis, C. Stefanadis (2011)
Vulnerable plaque and inflammation: potential clinical strategies.Current pharmaceutical design, 17 37
G. Petty, Robert Brown, J. Whisnant, J. Sicks, W. O'fallon, D. Wiebers (1999)
Ischemic stroke subtypes: a population-based study of incidence and risk factors.Stroke, 30 12
B. Hudzik, A. Danikiewicz, J. Szkodziński, L. Polonski, B. Zubelewicz-Szkodzińska (2014)
Pentraxin-3 concentrations in stable coronary artery disease depend on the clinical presentationEuropean Cytokine Network, 25
J. Matsubara, S. Sugiyama, Toshimitsu Nozaki, K. Sugamura, M. Konishi, Keisuke Ohba, Y. Matsuzawa, E. Akiyama, E. Yamamoto, K. Sakamoto, Y. Nagayoshi, K. Kaikita, H. Sumida, S. Kim‐Mitsuyama, H. Ogawa (2011)
Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction.Journal of the American College of Cardiology, 57 7
Haibo Liu, Xiaofang Guo, K. Yao, Chunming Wang, Guo-guang Chen, Wei Gao, Jie Yuan, Wangjun Yu, J. Ge (2015)
Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart FailureBioMed Research International, 2015
E. Ammirati, F. Moroni, G. Norata, M. Magnoni, P. Camici (2015)
Markers of Inflammation Associated with Plaque Progression and Instability in Patients with Carotid AtherosclerosisMediators of Inflammation, 2015
A. Mantovani, C. Garlanda, B. Bottazzi, G. Peri, A. Doni, Y. Torre, R. Latini (2006)
The long pentraxin PTX3 in vascular pathology.Vascular pharmacology, 45 5
P. Chamnan, R. Simmons, S. Sharp, S. Griffin, N. Wareham (2009)
Cardiovascular risk assessment scores for people with diabetes: a systematic reviewDiabetologia, 52
R. Vasan (2006)
Biomarkers of Cardiovascular Disease: Molecular Basis and Practical ConsiderationsCirculation, 113
Giuseppe Peri, M. Introna, Domenico Corradi, Giuseppe Iacuitti, Stefano Signorini, Fausto Avanzini, Fabrizio Pizzetti, Aldo Maggioni, Tiziano Moccetti, Marco Metra, L. Cas, Pietro Ghezzi, Jean Sipe, Gianpietro Re, Giorgio Olivetti, Alberto Mantovani, Roberto Latini (2000)
PTX3, A prototypical long pentraxin, is an early indicator of acute myocardial infarction in humans.Circulation, 102 6
AbstractType 2 diabetes is contemporarily a major social and epidemiological problem and among others is a strong risk factor for cardiovascular diseases. Pentraxin 3, a potential early biomarker of atherosclerosis, is an acute-phase reactant produced by the peripheral tissues where the inflammation takes place. In this study we examined a group of patients with type 2 diabetes with and without cardiovascular complications compared to persons with normal glucose tolerance (patients with cardiovascular complications and healthy volunteers). Plasma pentraxin 3 concentration as well as some basic biochemical blood analysis were performed. Moreover, transcranial and carotid Doppler ultrasound examination as well as transthoracic echocardiography were performed. It turned out that there was an association of plasma pentraxin 3 concentration and carotid atherosclerosis found in the control group of patients with cardiovascular complications but with normal glucose tolerance. In the group of patients with type 2 diabetes and cardiovascular complications we have found an association of plasma pentraxin 3 concentration with diastolic left ventricular dysfunction. Additionally, in the group of patients with type 2 diabetes without cardiovascular disease plasma pentraxin 3 concentration was associated with elevated urinary albumin creatinine ratio. Further studies, on a larger group of patients, are required to confirm these observations.
Open Life Sciences – de Gruyter
Published: Apr 24, 2017
Access the full text.
Sign up today, get DeepDyve free for 14 days.